{"classes":[{"categories":[{"measurements":[{"comment":"Geometric mean and geometric coefficient of variation were not reported for n \\< 3.","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"23","value":"21.52"},{"groupId":"OG002","spread":"28","value":"69.63"},{"groupId":"OG003","spread":"36","value":"217.2"},{"groupId":"OG004","spread":"50","value":"21.24"}]}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"comment":"Geometric mean and geometric coefficient of variation were not reported for n \\< 3.","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"16","value":"30.10"},{"groupId":"OG002","spread":"52","value":"86.34"},{"groupId":"OG003","spread":"42","value":"402.6"},{"groupId":"OG004","spread":"29","value":"56.48"}]}],"title":"Cycle 4 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"15"}],"units":"Participants"}],"description":"Cmax was the maximum concentration after dose administration observed directly from the data.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received PF-06801591 0.5 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1186 days)","id":"OG000","title":"Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])"},{"description":"Participants received PF-06801591 1 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 659 days)","id":"OG001","title":"Part 1: PF-06801591 1 mg/kg (IV)"},{"description":"Participants received PF-06801591 3 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1606 days)","id":"OG002","title":"Part 1: PF-06801591 3 mg/kg (IV)"},{"description":"Participants received PF-06801591 10 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 445 days)","id":"OG003","title":"Part 1: PF-06801591 10 mg/kg (IV)"},{"description":"Participants received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 419 days)","id":"OG004","title":"Part 1: PF-06801591 300 mg (Subcutaneously [SC])"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Analysis population included all enrolled participants treated who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 1 and 24 hours post dose on Cycle 1 Day 1, and pre-dose and 1 hour post dose on Cycle 4 Day 1 in Part 1","title":"Maximum Plasma Concentration (Cmax) of PF-06801591 - Part 1","type":"SECONDARY","unitOfMeasure":"ug/mL"}